OJU1 Stock Chart & Stats
€3.60
€0.14(4.04%)
At close: 4:00 PM EDT
€3.60
€0.14(4.04%)
Day’s Range― - ―
52-Week Range€1.80 - €4.42
Previous CloseN/A
Volume0.00
Average Volume (3M)668.00
Market Cap
€190.67M
Enterprise Value€154.55
Total Cash (Recent Filing)€50.61M
Total Debt (Recent Filing)€733.00K
Price to Earnings (P/E)1.2
Beta0.45
Next Earnings
Jul 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.23
Shares Outstanding41,597,355
10 Day Avg. Volume686
30 Day Avg. Volume668
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetDebt-to-equity near zero and a sizable equity base reduce solvency pressure. This conservative structure gives Oramed room to fund clinical development or pursue partnerships without the constraints associated with heavily leveraged biotech peers.
Oral Biologic Delivery PlatformOramed’s focus on oral delivery of biologics targets a meaningful formulation challenge in diabetes. If development succeeds, an oral alternative could improve convenience and support differentiated partnering or licensing opportunities.
Flexible Licensing-Based MonetizationTechnology licensing can create non-linear revenue through upfront, milestone and royalty payments without requiring a full commercial sales infrastructure. This model provides strategic flexibility while candidates progress through development.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means clinical development is not self-funded. Continued cash burn may require financing, asset monetization or partnerships, creating execution and potential dilution risks over the medium term.
Weak Core Operating EconomicsLimited revenue and deeply negative EBIT indicate that reported profitability is not yet supported by a durable operating engine. This leaves results dependent on volatile non-operating items or transactions rather than recurring commercial performance.
Counterparty Repayment ExposureOramed remains exposed to the timing and form of Scilex repayment, including possible settlement in registered equity. Delays or equity settlement could weaken cash recovery, increase uncertainty and complicate capital allocation.
Oramed Pharm News
OJU1 FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was €1.80 and its highest was €4.42 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is €190.67M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jul 14, 2027 which is in 320 days.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Jul 15, 2026. The company reported €1.594 earnings per share for the quarter, beating the consensus estimate of €0.373 by €1.221.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 41,597,355 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of €1.594 in its last earnings report, beating expectations of €0.373. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:OJU1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
128.62%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Technical Analysis
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
ALX Oncology Holdings
―
Spruce Biosciences
―